Trial comparing treatments for Colorectal Cancer
Official title A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
ClinicalTrials.gov ID: NCT07525206
What this study is testing
What is Telisotuzumab adizutecan?
This is an investigational medicine being studied as a potential treatment for colorectal cancer. is designed to target and kill cancer cells that have a specific protein called c-Met on their surface.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares side‑effects and disease changes when using telisotuzumab adizutecan with bevacizumab against the usual oral drug LONSURF plus bevacizumab in people whose cancer has not responded to other treatments.
- Who it's for
- Adults with metastatic colorectal cancer that has not responded to prior therapy
- What's involved
- Participants are randomly assigned to receive either the new IV drug plus bevacizumab or the standard oral drug plus bevacizumab. They will have regular clinic visits, blood tests, questionnaires and medical checks to monitor treatment effects and side‑effects.
- Time commitment
- The study lasts about 36 months, with frequent visits at a hospital or clinic for assessments and blood work.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Must voluntarily sign and date an informed consent, approved by an Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation...
- Life expectancy \>= 12 weeks per investigator assessment
You likely can't join if
- Prior systemic regimen containing c-Met targeting agent (e.g., antibody, antibody drug conjugate, bispecific) or any Top-1 inhibitor ADC.
- History of intolerance, allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to...
- History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
- History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
The study team makes the final eligibility decision.
Where it is enrolling
- Goodyear, Arizona, United States
- Springdale, Arkansas, United States
- Duarte, California, United States
- Aurora, Colorado, United States
- New Haven, Connecticut, United States
- Tampa, Florida, United States
- Newnan, Georgia, United States
- Chicago, Illinois, United States
- Kansas City, Missouri, United States
- East Brunswick, New Jersey, United States
- Lake Success, New York, United States
- Durham, North Carolina, United States
- Cincinnati, Ohio, United States
- Portland, Oregon, United States
- Abilene, Texas, United States
- Houston, Texas, United States
- Blacksburg, Virginia, United States
- Seattle, Washington, United States
- Bonheiden, Antwerpen, Belgium
- Edegem, Antwerpen, Belgium
+ 59 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Goodyear, Arizona, United States; Springdale, Arkansas, United States; Duarte, California, United States; Aurora, Colorado, United States; New Haven, Connecticut, United States; Tampa, Florida, United States and 73 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.